I already know the news! Latest launch date of Moboxertinib

The U.S. Food and Drug Administration (FDA) approved Mobocertinib/Mobocertinib (Mobocertinib) under the trade name exkivity in September 2021 for the treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR exon 20 insertion mutations who have failed previous treatment. Mobosetinibreceived Priority Review and received FDA Breakthrough Therapy Designation, Fast Track Designation and Orphan Drug Designation. It is the first and only approved oral treatment drug specifically targeting EGFR exon 20 insertion mutations.

The FDA also approved Thermo Fisher Scientific's Oncomine Dx Target test as a companion diagnostic for NGS to identify patients with non-small cell lung cancer with EGFR exon 20 insertions. NGS testing is critical for these patients because it allows for more accurate diagnosis compared to polymerase chain reaction (PCR) testing. The approval of mobosertinib marks another important step forward, providing physicians and patients with a new targeted oral therapy designed specifically for this patient population that has demonstrated clinically meaningful and sustained responses.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.